|

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

RECRUITINGPhase 1/2Sponsored by Betta Pharmaceuticals Co., Ltd.
Actively Recruiting
PhasePhase 1/2
SponsorBetta Pharmaceuticals Co., Ltd.
Started2026-01-29
Est. completion2028-12-28
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing.
* Have received prior standard therapy appropriate for tumor type and stage.
* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function.

Exclusion Criteria:

* Primary central nervous system (CNS) tumors active and untreated brain metastases.
* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication.
* History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy

Conditions6

Advanced Solid TumorsCancerColorectal Cancer (CRC)Lung CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.